Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Recent observations have suggested a role of neutrophil extracellular traps (NETs) in the
pathophysiology of severe COVID-19. The aim of the study is to assess efficacy and safety of
aerosolized DNase I to remove NETs and decrease respiratory distress in patients with
COVID-19.